TD-106 |
| Catalog No.GC33068 |
TD-106은 표적 단백질 분해에 사용할 수 있는 세레블론(CRBN) 조절제입니다. TD-106이 있는 BRD4 PROTAC은 BRD4 분해를 유도합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2250288-69-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
TD-106 is a cereblon (CRBN) modulator, which can be used for targeted protein degradation. BRD4 PROTACs with TD-106 induce BRD4 degradation[1].
TD-106 (0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM, 10 μM, and 100 μM; 72?hours) inhibits the proliferation of NCI-H929 myeloma cell line with an CC50?of?0.039?μM[1].TD-106 (1, 10, 100, and 1000 nM) induces the degradation of IKZF1/3 in NCI-H929?cells[1].|| Cell Cytotoxicity Assay[1]||Cell Line:|NCI-H929?cells|Concentration:|72?hours|Incubation Time:|0.1 nM, 1 nM, 10 nM, 100 nM, 1000 nM, 10 μM, and 100 μM|Result:|Inhibited cell proliferation with an CC50?of?0.039?μM.
TD-106 (50 mg/kg; intraperitoneally; q.d. for 14 days) possesses anti-myeloma activity in SCID mice with TMD-8 xenograft model.|| Animal Model:|Female SCID (CB-17/IcrCri-scid) mice with TMD-8 xenograft model[1]|Dosage:|50 mg/kg|Administration:|Intraperitoneally (i.p.); q.d. for 14 days|Result:|Treatment inhibited tumor growth during this duration.
[1]. Kim SA, et al. A novel cereblon modulator for targeted protein degradation. Eur J Med Chem. 2019 Mar 15;166:65-74.
Average Rating: 5 (Based on Reviews and 4 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *